



Teva Innovative Medicine Pipeline



Technology platforms



Pipeline is current as of November 1, 2024

1. In collaboration with MODAG.
2. In collaboration with Sanofi
3. In collaboration with Launch Therapeutics

Teva innovative medicine pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.

Teva Biosimilar Franchise



TEV-'285

 TEV-'261

 TEV-'289

 TEV-'294¹

 TEV-'292¹

 TEV-'295¹

 TEV-'296¹

 TEV-'316²

 TEV-'333²

Biosimilar to Xgeva[®] (denosumab)

 Biosimilar to Xolair[®] (omalizumab)

 Biosimilar to Eylea[®] (aflibercept)¹

 Biosimilar to Simponi[®] (golimumab)¹

 Biosimilar to Simponi Aria[®] (golimumab)¹

 Biosimilar to Entyvio[®] (vedolizumab)¹

Biosimilar to Prolia[®] (denosumab)



Herzuma[®] (trastuzumab-pkrb)³
 For Injection - 420 mg/vial - 150 mg/vial

Truxima[®] (rituximab-abbs)³
 Injection for intravenous use 500 mg/50 mL - 100 mg/10 mL

Ranivisio[®]
 10 mg/ml solution for injection (ranibizumab)⁴

Simlandi[®] (adalimumab-ryvk)¹
 Injection - 40mg/0.4mL

TevaGrastim[®]
 Solution for injection or infusion
Filgrastim[®]⁵

Bevacizumab-Teva[®]⁶

Pipeline is current as of November 1, 2024

1. In collaboration with Alvotect for the U.S. Market
2. In collaboration with mAbxience
3. In collaboration with Celltrion in the U.S. and Canada
4. In collaboration with BioEq in the UK (marketed as ONGAVIA[®]), in the EU (marketed as RANIVISIO[®]) and in Canada (marketed as RANOPTO[™])
5. On market in EU and other IM countries
6. In collaboration with mAbxience in Switzerland

Teva biosimilar pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.